

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the Application:

Claim 1-20 (cancelled)

Claim 21 (currently amended): Pharmaceutical composition characterized by comprising a combination of an effective dose of inulin and of an anti-metabolic anti-cancer drug, wherein said inulin and said anti-metabolic anti-cancer drug in combination providing provide a synergistic anti-cancer therapeutic effect to a human or non-ruminating animal undergoing treatment for cancer.

Claim 22 (previously presented): Pharmaceutical composition according to claim 21, wherein the inulin is inulin with a DP up to about 100, or oligofructose or a mixture thereof.

Claim 23 (previously presented): Pharmaceutical composition according to claim 21, wherein the inulin is chicory inulin with a (\overline{DP}) ranging from about 10 to about 30, or oligofructose with a (DP) ranging from 2 to 7 and containing about 5 wt% in total of glucose, fructose and sucrose.

Claim 24 (previously presented): Pharmaceutical composition according to claim 21, wherein the anti-cancer drug is selected from the group consisting of methotrexate, cytarabin, fluorouracil, mercaptopurin, thioguanin, azathioprin and hydroxycarbamide.

Claim 25 (previously presented): Pharmaceutical composition according to claim 24 wherein the anti-cancer drug is 5-fluorouracil or methotrexate.

Claim 26 (previously presented): Pharmaceutical composition according to claim 21, which additionally to the said anti-metabolic anti-cancer drug contains one or more anti-cancer

drugs belonging to the class of anti-metabolic anti-cancer drugs and/or to another class of anti-cancer drugs.

Claim 27 (previously presented): Pharmaceutical composition according to claim 21, in which the inulin and the anti-metabolic anti-cancer drug which constitute the combination are present in the same galenic formulation.

Claim 28 (previously presented): Pharmaceutical composition according to claim 21, in which the inulin and the anti-metabolic anti-cancer drug which constitute the combination are present in separate galenic formulations which in combination together form the pharmaceutical composition.

Claim 29 (previously presented): Pharmaceutical composition according to claim 21, which is suitable for oral, parenteral or rectal administration, or for tube feeding.

Claim 30 (previously presented): Pharmaceutical composition according to claim 28 in which the inulin is present in a functional food or feed.

Claim 31 (previously presented): Pharmaceutical composition according to claim 28 in which the anti-cancer drug is present in a formulation which is suitable for oral or parenteral administration.

Claim 32 (previously presented): Pharmaceutical composition according to claim 21 for use as a medicament for the treatment of cancer in human.

Claim 33 (previously presented): Pharmaceutical composition according to claim 21 for use as a medicament for the treatment of cancer in non-ruminating mammals.

Claim 34 (cancelled)

Claim 35 (previously presented): Method for the treatment of cancer in a human or in a non-ruminating mammal comprising administering to said being in need of such treatment an effective amount of a pharmaceutical composition as defined in claim 21.

Claim 36 (previously presented): Method according to claim 35 wherein the inulin and the anti-metabolic anti-cancer drug of the combination forming the pharmaceutical composition are present in the same galenic formulation constituting the pharmaceutical composition.

Claim 37 (previously presented): Method according to claim 35 wherein the inulin and the anti-metabolic anti-cancer drug of the combination forming the pharmaceutical composition are present in separate galenic formulations constituting together the pharmaceutical composition.

Claim 38 (previously presented): Method according to claim 37 wherein the separate galenic formulations are administered simultaneously or non-simultaneously.

Claim 39 (previously presented): Method according to claim 37 wherein the separate galenic formulations are administered via different methods of administration and the inulin is administered by a method selected from the group consisting of oral, parenteral or rectal administration and administration via tube feeding.

Claim 40 (previously presented): Method according to claim 39 wherein the separate galenic formulation containing the inulin is a functional food or feed.

Claim 41 (previously presented): Pharmaceutical composition according to claim 28, wherein the separate galenic formulations which in combination form the pharmaceutical composition are suitable for oral, parenteral or rectal administration, or for tube feeding.

Claim 42 (previously presented): Pharmaceutical composition according to claim 41,
wherein the separate galenic formulations are suitable for administration in a different manner
from each other.

HAYES SOLOWAY P.C.
130 W. CUSHING STREET
TUCSON, AZ 85701
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567